FOXC2 and cancer: FOXC2 was an independent predictor of time to clinical recurrence (HR 1.8, p = 0.023), skeletal metastasis (HR 3.7, p = 0.004) and cancer specific death (HR 4.8, p = 0.001), together with the EN‐switch and Gleason grade groups (GG3 [4+3] versus GG2 [3+4]) (Table 3).